NSA Digital Archive/E+ via Getty Images Introduction It's time to talk big-picture stuff. However, before I get to the main message, I wanted to share a chart I just came across. As we are currently in a very volatile pre-election period with a load of political uncertainty, Ritholz Wealth Management produced a chart that shows the S&P 500 returns during presidential terms - including the max drawdown. Ritholz Asset Management One thing clearly becomes obvious: (almost) every single president has gone t ...

Danaher Corporation’s (DHR) second-quarter 2024 adjusted earnings (excluding 50 cents from non-recurring items) of $1.72 per share surpassed the Zacks Consensus Estimate of $1.57. The bottom line declined 0.6% year over year.Danaher’s net sales of $5.7 billion outperformed the consensus estimate of $5.6 billion. However, the metric declined 3% year over year due to lower core sales in the Biotechnology segment.Organic sales decreased 3.5%. Acquisitions had a positive impact of 2% on quarterly sales while ad ...

Key TakeawaysDanaher's second-quarter results beat analysts' expectations on both profit and revenue.CEO Rainer Blair cited "positive momentum" in Danaher's bioprocessing business and "strong performance" in molecular testing subsidiary Cepheid.Danaher affirmed its guidance that non-GAAP core revenue will decline by a low-single-digit percentage year-over-year. Danaher Corp. (DHR) beat analysts' expectations on the top and bottom lines with its second-quarter results, sending shares higher in intraday tradi ...

The biotechnology, diagnostics, and life sciences company looks set to return to its long-term growth rate.Danaher's (DHR 7.12%) core revenue decline of 3.5% in the second quarter might not seem like anything to write home about. Still, as ever in investing, it's about context, and the company's earnings report shows that it's set to return to its long-term growth track.The good news encouraged investors to bid the stock up by more than 7% in trading before 10 a.m. ET today.Danaher beats guidanceAs you migh ...

Danaher Corporation (NYSE:DHR) Q2 2024 Earnings Conference Call July 23, 2024 8:00 AM ET Company Participants John Bedford - VP of IR Rainer M. Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Jack Meehan - Nephron Research Rachel Vatnsdal - J.P. Morgan Scott Davis - Melius Research Vijay Kumar - Evercore ISI Michael Ryskin - Bank of America Securities Daniel Brennan - TD Cowen Douglas Schenkel - Wolfe Research Tycho Peterson - Jefferies Operator Good morning. My name is Todd, an ...

Danaher (DHR) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.57 per share. This compares to earnings of $2.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.55%. A quarter ago, it was expected that this industrial and medical device maker would post earnings of $1.72 per share when it actually produced earnings of $1.92, delivering a surprise of 11.63%.Over the last four quar ...

Danaher Corporation Second Quarter 2024 Earnings Release July 23, 2024 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forwardlooking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those sugg ...

Key Points - Danaher Corporation reported net earnings of $907 million for the quarter ended June 28, 2024, translating to $1.22 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.72 [1][5][11] - Revenues decreased by 3.0% year-over-year to $5.7 billion, with non-GAAP core revenue down 3.5% [1][11] - Operating cash flow was reported at $1.4 billion, while non-GAAP free cash flow was $1.1 billion [1][12] - The company expressed satisfaction with the performance of its bioprocessing business and Cepheid, indicating market share gains in molecular testing [1][3] - Danaher anticipates low-single digit declines in non-GAAP core revenue for both the third quarter and full year 2024 [1][11] Financial Performance - For the three-month period ended June 28, 2024, total sales were $5.743 billion, down from $5.912 billion in the same period last year [5][11] - Gross profit for the quarter was $3.428 billion, with operating profit at $1.168 billion [6][11] - The company reported a year-over-year decline in net earnings from continuing operations, which was $907 million compared to $920 million in the previous year [5][11] Segment Performance - The biotechnology segment experienced a sales decline of 9.0%, while life sciences and diagnostics segments saw declines of 1.5% and growth of 1.5%, respectively [11] - Core sales growth was reported as a decline of 3.5% for the three-month period, with a forecasted decline of low-single digits for the upcoming periods [11][12] Cash Flow Analysis - Total cash flow from continuing operations was $1.417 billion for the quarter, down from $1.646 billion year-over-year [12] - Free cash flow from continuing operations was reported at $1.131 billion, reflecting a decrease from $1.319 billion in the previous year [12]

Exhibit 99.1 Innovation at the speed of life Danaher Reports Second Quarter 2024 Results WASHINGTON D.C., July 23, 2024 -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Second Quarter 2024 Results • Net earnings were $907 million, or $1.22 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.72. • Revenues decreased ...

Sundry Photography I last covered Danaher Corporation (NYSE:DHR) in April, discussing the company's good medium to long-term prospects. While the stock experienced a high single-digit percentage increase from my article until mid-June, it has since given up most of its gains and is now trading at the same level as when the previous article was published. The company is due to report its earnings on 23rd July before the market opens. If we go by commentary from some of the company's peers in the bioprocessin ...